CORRECT

NCT01103323 📎

Regimen

Experimental
Regorafenib 160 mg QD (3 weeks on/1 week off) + BSC
Control
Placebo + BSC

Population

Metastatic CRC, 3L+, refractory to all standard therapies including fluoropyrimidine/oxaliplatin/irinotecan/anti-VEGF/anti-EGFR (KRAS WT).

Key finding

3L+ mCRC (post-all-standard-therapies): mOS 6.4 vs 5.0 mo (HR 0.77, 95% CI 0.64-0.94, p=0.0052); disease control rate 41% vs 15% (p<0.0001); regorafenib 160mg d1-21 q28d; grade 3+ HFSR 17%, fatigue 10%, diarrhea 7%, hypertension 7%

Source: PMID 23177514

Timeline

    Guideline citations

    • NCCN Colon (p.33)
    • NCCN Rectal (p.43)